Diacomit (stiripentol) is an antiepileptic drug applied in specialized therapeutic contexts, commonly used as an adjunctive treatment to address the severe, uncontrolled seizure activity characteristic of its primary indication.

---

Targeting Refractory Seizures in Dravet Syndrome

Diacomit is indicated for the adjunctive management of seizures associated with Dravet syndrome (Severe Myoclonic Epilepsy of Infancy) in patient groups where use is relevant, including children and adolescents on existing therapy. It is applied in clinical situations where the recurrent, convulsive episodes—specifically generalized tonic-clonic and clonic seizures—are characterized by refractory patterns, which means they are not easily managed by initial treatment approaches. The medication is relevant for managing symptoms that interfere with daily comfort, and is commonly used across conditions presenting with acute or disruptive episodic manifestations. Its use is supported by clinical observations that the treatment may assist with maintaining periods of stability.

“This therapy is commonly used for managing the challenging symptomatic phases associated with drug-resistant epilepsy.”

Quick Fact: Relevant for Refractory Convulsive Seizures

---

Reducing Seizure Frequency and Burden

The therapeutic benefit generally helps to ease the frequency of these major convulsive seizure events. By easing how often these severe episodes occur, the medication supports the overall degree of seizure control. This support contributes to easing the overall symptom load associated with recurrent severe episodes, and supports general well-being during symptomatic phases. Diacomit is generally used to help with symptoms related to heightened neurological activity, specifically the cluster of symptoms associated with severe, drug-resistant epilepsy.

Eligibility Map: Who Can and Cannot Use Diacomit?

This information is based strictly on governmental regulatory documents (FDA, EMA) defining the population eligible to use Diacomit (stiripentol) for seizures associated with Dravet syndrome.

---

Eligibility Scope	Status/Restriction
Populations for whom use is allowed	Patients 6 months of age and older who weigh at least 7 kg (15 lbs).
Populations for whom use is contraindicated	Patients with a past history of psychoses with attacks of delirium (European labeling).
Populations for whom use is not recommended	Patients with impaired hepatic and/or renal function.

---

Age-Related and Conditional Rules	Status/Restriction
Infants under 6 months	Safety and effectiveness have not been established.
Monotherapy Use	Not approved; Diacomit is restricted to adjunctive treatment alongside other antiepileptic drugs like clobazam.
Older Adults (geq 65)	Long-term data has not been collected in a sufficient number of this population to confirm maintenance of effect.
Phenylketonuria (PKU)	The powder for oral suspension contains phenylalanine and must be considered in the patient's total daily intake.

---

Connection to the overall eligibility profile

Regulatory documents strictly define who can and cannot use the medicine by setting absolute minimum age and weight thresholds, mandating that the medicine be used only in combination with other specified drugs (adjunctive use), and establishing formal exclusions based on specific pre-existing conditions. This ensures the medicine is administered only within the population parameters defined by official regulatory review.

Interactions with other medicines and products

Diacomit (stiripentol) is documented in official regulatory sources to cause pharmacokinetic interactions by acting as a potent inhibitor of multiple drug-metabolizing enzymes, specifically CYP2C19, CYP3A4, and CYP2D6. Stiripentol also inhibits the drug transporters P-glycoprotein (P-gp) and BCRP. These inhibitory effects lead to a clinically significant increase in the plasma concentrations of many co-administered medicinal products.

Pharmacokinetic Interactions and Exposure

Co-administration with stiripentol results in a significant increase in the exposure of other antiepileptic drugs, including clobazam (2- to 3-fold) and its active metabolite, norclobazam (up to 5-fold). Stiripentol is also documented to increase the plasma levels of phenytoin and phenobarbital.

Formal Regulatory Restrictions and Contraindicated Combinations

Official prescribing information places mandatory restrictions on combining Diacomit with certain substances:

• Antiepileptic Drugs: Carbamazepine, phenytoin, and phenobarbital should not be used in conjunction with stiripentol in the context of Dravet syndrome treatment.
• Other Drugs: Undesirable combinations include Rye Ergot Alkaloids and certain drugs that carry a risk of cardiac arrhythmias (e.g., pimozide, quinidine).
• CNS Depressants: Co-administration with alcohol and other Central Nervous System depressants is documented to potentiate effects such as somnolence.

Interactions with Ingested Substances

Regulatory documents explicitly state that Diacomit must not be taken with milk or dairy products, carbonated drinks, fruit juice, or food and drinks that contain caffeine or theophylline.

How Diacomit Works: Mechanism of Action

Diacomit (stiripentol) modulates neuronal excitability primarily through two interconnected pharmacological mechanisms.

---

GABA A Receptor System Modulation

One mechanism involves the positive allosteric modulation of the gamma-aminobutyric acid ( GABA)-A receptor complex in the central nervous system. Stiripentol binds to a site distinct from the GABA binding site, increasing the frequency of chloride channel opening when GABA is present. This molecular interaction enhances the inhibitory conductance of the receptor, resulting in an overall increase in neuronal inhibitory tone that reduces neuronal hyperexcitability within the targeted circuits.

---

Cytochrome P450 Enzyme Inhibition

The second mechanism involves the inhibition of key Cytochrome P450 (CYP) isoenzymes, particularly CYP2 C19 and CYP3 A4. These enzymes are critical for the hepatic metabolism of various co-administered therapeutic agents. Inhibition of these enzymes modifies the pharmacokinetics of these agents, leading to increased plasma concentrations and sustained systemic exposure.

How Diacomit is Used: Official Administration Guidelines

Diacomit (stiripentol) is officially approved for oral use only and is administered as an adjunctive therapy alongside other antiepileptic drugs. Official guidelines require dosing to be strictly weight-based, with a target maintenance dose of 50 mg/kg/day up to a maximum total daily dose of 3,000 mg.

The total daily dosage must be split into 2 or 3 divided doses. Treatment initiation involves a gradual dose escalation (titration) over several weeks to safely reach the full maintenance amount.

A crucial condition of use is the timing of intake: the medicine must be taken with a meal. Standard administration guidelines specify not taking Diacomit with milk, dairy products, fruit juices, carbonated drinks, or any foods or drinks containing caffeine or theophylline.

---

Administration Specifics

Entity	Instruction
Dosage Forms	Capsules (250 mg, 500 mg) and Powder for Oral Suspension (250 mg, 500 mg) are available.
Preparation	Capsules must be swallowed whole with water. The powder must be mixed into a glass of water and taken immediately.
Age and Function	Indicated for patients 6 months of age and older weighing at least 7 kg. Use is not recommended in patients with known hepatic or renal impairment.
Discontinuation	If the long-term regimen is stopped, the dose must be gradually reduced (tapered) to avoid potential risks associated with abrupt cessation.
Missed Dose	Do not double the next dose if one is missed; skip the missed dose if it is almost time for the next scheduled dose.

Research Evidence / Overview of Studies for Diacomit (Stiripentol)

---

Evidence for Use in Refractory Seizures Associated with Dravet Syndrome

Research for Diacomit has primarily focused on its use as an additional treatment for the severe, uncontrolled seizures associated with Dravet syndrome. This is a condition characterized by fluctuating or episodic manifestations, where previous treatments have been the subject of research. The core evidence for this application comes from two major clinical research efforts—short-term studies known as randomized, double-blind, placebo-controlled trials. In these studies, researchers were examining how often generalized clonic and tonic-clonic seizures occurred in the enrolled patients. The primary aim was to measure the proportion of patients who experienced a predefined level of change in seizure frequency.

How Stiripentol Was Compared to Other Treatments

The pivotal research for Diacomit was evaluated as an adjunctive (add-on) therapy. The studies explored whether adding stiripentol to an existing regimen, particularly one including clobazam, was associated with different observed patterns compared to simply adding an inactive substance (placebo) to the same existing regimen. The research examined patterns in the frequency measurements by comparing the group receiving stiripentol plus standard therapy versus the group receiving placebo plus standard therapy. The design was used to explore the measurements associated with introducing the new medicine.

Long-Term Studies and Follow-Up

The primary, controlled evidence phase used to establish the initial profile was of a short duration, lasting only two months. To gather more information about how patients fare over time, open-label extension (OLE) studies and retrospective observational studies were conducted. These studies monitored patients for longer periods, with some follow-up durations extending for up to several years. While this evidence contributes to understanding symptom patterns over time and may provide insight into short-term changes, there is limited information for long-term outcomes regarding the sustained maintenance of the observed effects.

Key Studies & References Stiripentol (Diacomit) - Executive Summary (Review of STICLO trials and long-term data)

Common questions about Diacomit (FAQ)

---

Q: How long can a patient expect to be on Diacomit (stiripentol) treatment?

Regulatory documents indicate that Diacomit is used as part of a long-term treatment plan for seizures associated with Dravet syndrome. If Diacomit treatment is discontinued, the dose is typically withdrawn gradually, rather than abruptly. The requirement for regular safety monitoring, such as blood counts every six months, is part of the long-term safety monitoring associated with its use.

---

Q: Can I drink alcohol while taking Diacomit?

Regulatory warnings state that combining Diacomit with alcohol or other central nervous system depressants may increase side effects such as sleepiness or dizziness. Diacomit's official medication guide advises caution. The decision to consume alcohol while on this medication is a matter for discussion between the patient and their healthcare provider.

---

Q: Does Diacomit interact with any herbal supplements?

Official drug labeling emphasizes that Diacomit can interact with many other prescription and non-prescription medicines due to its effects on liver enzymes. The medication label recommends informing the healthcare provider about all products being used, including over-the-counter medicines, vitamins, and any herbal supplements, to prevent potential drug interactions.

---

Q: Can Diacomit be crushed or opened to mix with food instead of water?

According to official prescribing information, Diacomit capsules must be swallowed whole with water during a meal and should not be broken or opened. The powder for oral suspension is designed to be mixed in a glass of water and must be taken immediately during a meal.

---

Q: What is the correct procedure for safely discarding expired Diacomit?

Official regulatory documents state that any unused or expired Diacomit should be disposed of in accordance with local requirements. Following general drug disposal guidelines, the product may often be mixed with an undesirable substance, such as used coffee grounds, placed in a sealed container, and disposed of in household trash.

Storage and Disposal of Diacomit (Stiripentol)

Diacomit must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with transient excursions permitted up to 30 C. It is mandatory to keep the product from freezing and to store it away from heat, moisture, and direct light.

Container and Stability

The medicine must be kept in its original, closed container and stored out of the reach of children. The powder for oral suspension must be taken immediately after mixing with water and must not be stored once prepared.

Disposal

Unused or expired Diacomit, including waste material, must be disposed of in accordance with local requirements. Patients should consult a healthcare professional regarding the appropriate method for discarding unused medicine.